Back to search

Article

Amyloid β oligomers enhance presynaptic exocytosis via CaV2.1 to drive disease progression in Alzheimer’s models

2024-09-30

Abstract excerpt

<title>Abstract</title> <p> Mixed outcomes in clinical trials of amyloid β-lowering agents for Alzheimer’s disease (AD) make the identification of alternative candidate molecular targets for therapy a priority. However, limited understanding of molecular pathways mediating the effects of amyloid β on synaptic and cognitive function hampers these efforts. Here, we uncover an ENaC-Ca <sub>V</sub> 2.3-PKC-GSK-3β...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f40aea72-1fb2-5b25-90f9-16c01df645a4
DOI
10.21203/rs.3.rs-1638917/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Amyloid β oligomers enhance presynaptic exocytosis via CaV2.1 to drive disease progression in Alzheimer’s modelsDOI 10.21203/rs.3.rs-1638917/v1
Select a neighboring publication to make it the new centre.